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It has been proposed that humans and
wildlife have suffered adverse effects on
reproductive health as a result of environ-
mental exposure to chemicals that interact
with the endocrine system (1-4). Mindful
that a hypothesis is an idea that has not been
sufficiently tested (5), many independent
efforts have been undertaken to evaluate the
scope and legitimacy ofthe problem. As one
ofthese undertakings, the European Centre
for Ecotoxicology and Toxicology of
Chemicals (ECETOC) convened the pre-
sent study group with the aims ofdiscerning
the degree to which synthetic chemicals are
implicated in this issue and advising toxicol-
ogists and ecotoxicologists on appropriate
testing methods and hazard identification
strategies. After compiling a list ofcurrently
available test methods (6), we turned our
attention to the identification of practical
tests for endocrine disruption. To do that,
we assumed that a range of endocrine dis-
ruption hazards are posed to wildlife and
humans by environmental chemicals. We
recognize the importance to any future regu-
latory initiatives in this area of demonstrat-
ing dose-response relationships, establishing
the relevance of experimental models to
humans and wildlife, and assessing expo-
sures. However, these tasks were considered
to be beyond our initial purpose.
In support of attempts to develop an
appropriate hazard identification strategy
for endocrine-disrupting chemicals, several
regulatory initiatives have been launched,
the most specific being a mandate by
Congress that the EPA should have a regu-
latory framework on endocrine disruption
in place by 1998 (7). Such a condensed
time frame carries with it the potential for
the premature endorsement of unvalidated
assays and unrefined testing strategies. This
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article outlines some of these potential
problems with a view to their clear recog-
nition and circumvention.
The Potential Problems
Kavlock et al. (8) recently conducted a
definitive review of data that are cited to
support links between a range of human
health effects and exposure to endocrine-
disrupting chemicals. The key conclusions
of that analysis are presented in Table 1.
These authors concluded that there are no
clear relationships between endocrine
effects in humans and exposures to xenobi-
otics. These conclusions are further dissect-
ed in Table 2 according to the criteria rec-
ommended by Hill (9) for distinguishing
between epidemiological association and
causation, as recommended by Kavlock et
al. (8). For comparative purposes, the data
supporting causation for the 56 established
human carcinogens are also presented.
That analysis reveals only tentative associa-
tions between human exposure to chemi-
cals and the observation of any of the
endocrine toxicities listed in Table 1; with
the exception ofthe clinical use ofdiethyl-
stilbestrol (DES), there are presently no
proven causations in humans. There are
also no data to support the assumptionthat
synthetic chemicals, as opposed to natural-
ly occurring chemicals (and in the case of
humans, dietary constituents, lifestyle, etc.)
are the most important etiologic contribu-
tors to the projected problem (1). A similar
assumption, now considered to be incor-
rect (10), was made in the early stages of
the study ofenvironmental carcinogenesis.
This all emphasizes that any moves to reg-
ulate chemicals showing endocrine-dis-
rupting properties should be cautionary
and based on confirmed evidence, all of
which currently derives from either wildlife
or experimental studies. Specifically, the
justification for any future regulatory
actions should not be based on the pre-
sumption that such moves will automatical-
ly alleviate the human health effects dis-
cussed by Kavlock et al. (8).
In contrast to the situation in humans,
several etiological links between exposure to
synthetic endocrine-disrupting chemicals
and adverse effects on wildlife have been
established, mainly in contaminated envi-
ronments (1-4). Nonetheless, the data sup-
porting some ofthe suspected environmen-
tal links are as fragile as those noted by
Kavlock et al. (8) for human effects. An
example ofthis is provided by the predomi-
nant role played by the natural hormones
estrone and 17p-estradiol, as opposed to
synthetic xenobiotics, in the partial femi-
nization offish exposed to effluent ofsome
municipal sewage treatment plants in the
United Kingdom (11-16).
Given that there is significant conserva-
tion among animal species in the mecha-
nisms that control sexual reproduction and
development, it is suggested that it will be
possible to adopt, at least initially, a common
strategy for the identification ofwildlife and
human endocrine disruptors. For example,
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Table 1. Conclusions drawn by Kaviock et al. (8) in relation to the data supporting endocrine-disrupting
chemicals producing the known orsuspected humantoxicities listed
Possible human
endocrine toxicities
Cancer
Breast
Testicular, ovarian
Reduced sperm quality
Reproduction
Neurological
Immunological
Conclusions drawn by Kavlock et. al (8)
*DDT/DDE/PCBs-conflicting data regarding their etiological
involvement
* EPA database on pesticides-no alertsto estrogenic mammary
gland carcinogenesis
*450 NTP studies; 10% ofstudies induce mammary gland cancer,
butchemicals unlikelyto be estrogenic
* Concomitant decline in uterine and male breast cancer observed
*No evidencethatendocrine-disrupting chemicals are a riskfactor
*The generality ofthe effect and its etiology are farfrom certain
* First priority: hypotheses generated from field observations must
betested
* First priority: studies to define the biological effects most likely
to occur must be conducted
*Studiesto determine ifthere has been an increase in cases of
immune dysregulation should be conducted
Abbreviations: PCBs, polychlorinated biphenyls; EPA, U.S. Environmental Protection Agency; NTP,
National Toxicology Program.
Table 2 The nine criteria suggested by Hill (9) fordistinguishing associations and causations in epidemiologi-
calstudies, asappliedtothetwo areasshowna
Hill criteria for The 56 chemical Chemical endocrine
establishing causation carcinogens to humans toxicities in humans
Strength (ofevidence) + _b
Consistency (ofevidence) +
Specificity (ofeffect) +
Temporality (ofeffect) +
Dose response (ofeffect) +
Plausibility (ofeffect) + +
Coherence (with existing knowledge) + +
Experiment(simulation in rodents) + ?
Analogy(structure activity) + ?
+,criteriaforcausation met-,criteriaforcausation notmet;?, criteria partiallymet
"Structure-activity relationships are poorly defined in endocrine toxicity. Many endocrine toxicities have
been produced in rodents, butthese do not necessarily simulate effects in humans as only diethylstilbe-
strol is available forstudy.
bExceptdiethylstilbestrol.
the fact that a chemical can induce the pro-
duction of the female-specific protein vitel-
logenin in male fish raises the possibility
that it may cause corresponding effects in
other wildlife and in appropriately exposed
humans. Likewise, the activityofan agent in
a rodent uterotrophic assay contributes to
assessment of its potential to cause
endocrine toxicities in wildlife. Differences
between the assessment of wildlife and
human toxicities will most likely be encoun-
tered at the level ofthe nature, timing, dura-
tion, andmagnitude ofexposures, i.e., at the
level ofrisk assessment. On some occasions,
differences in the physiology or biochem-
istry of the reproductive process between
species or differences in the accumulation of
chemicals between the major environmental
compartments may become important risk
modifying factors. However, it is suggested
that such differences (e.g., the possibly
unique effects ofchemicals on metamorpho-
sis or molting) should be specifically studied
to determine their importance, rather than
being used to fragment the study of
endocrine disruption at this early stage.
Definitions andTerminology
A surge of studies to define chemical
endocrine disruptors, coupled with at-
tempts to solve problems created by pre-
liminary studies, is leading to a confusion
of terms. For example, agents are already
being labeled as estrogenic based on their
activity in the MCF-7 assay (the E-
SCREEN) (17) despite the fact that a range
of non-estrogenic factors can stimulate
these cells to divide (18), and the fact,
common to all of biology, that not all
activities observed in vitro are realized in
vivo. Alternatively, the absence of agreed-
upon definitions could lead to unrelated
activities of a chemical being linked with
the implication of a mechanistic associa-
tion. For example, it is superficially attrac-
tive to assume that the activityofbutylben-
zyl phthalate (BBP) in the MCF-7 assay
(17) is directly predictive of its reported
ability to reduce testis weight in rats (19).
However, BBP and its principal metabo-
lites are inactive in immature and ovariec-
tomized rat uterotrophic assays [(20); M.A.
Martens, unpublished data], and its activity
as a testicular toxin remains to be con-
firmed and explained. Similarly, the obser-
vation that continuous subcutaneous infu-
sion ofnonyl phenol is capable ofstimulat-
ing cell division in female rat mammarytis-
sue (21) was suggested to be unrelated to
its uterotrophic activity in the rat following
intraperitoneal injection (22), and the abil-
ity of the anti-estrogen raloxifene to
counter bone density loss in ovariec-
tomized rats (23) was recently shown not
to involve the DNA-binding domain ofthe
estrogen receptor with which this chemical
is known to interact (24). These recent
examples illustrate the complexity of the
biological issues being approached, and
they serve to warn against the precipitate
adoption ofsimplistic definitions and test-
ingstrategies.
It is therefore suggested that there is a
need for a set of toxicological definitions
that will serve this new area. For example,
there are two current definitions of an
estrogen-a compound that binds to iso-
lated estrogen receptors, and a compound
that produces trophic effects on the female
reproductive tract. However, what is
required is a definition of the toxic effects
expected of exposure of a whole organism
to such a chemical, a definition that may
differ between species and sexes. In the
absence ofsuch guidance it will be easy to
drift into hypothesis-fulfilling condusions.
For example, an agent may show evidence
ofpotential estrogenic activity by virtue of
its activity in one of the many available in
vitro assays, and then be administered to
animals to confirm the expression of this
toxic potential in vivo. However, if there
are no agreed-upon expected toxicities, the
chemical's ability to affect kidney weights
or thyroid gland function, for example,
may be taken as automatic confirmation of
the original prediction. Such empirical
associations may mislead, as illustrated by
the three examples cited above.
The collective term endocrine disruptor
is coming into general use, but it has yet to
be defined. We suggest that an endocrine
disruptor should be defined in reference to
an intact endocrine system, i.e., as an agent
that can induce adverse health effects in an
intact organism, consequent to disruption
of the organism's endocrine system. Other
potentially relevant properties ofthe chemi-
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cal, induding any effects observed in vitro,
can only contribute to its definition as a
potential endocrine disruptor. Specifically,
the activity ofachemical in anyofthe avail-
able in vitro assays does not define it as an
endocrine disruptor, any more than does
the demonstration ofa chemical's abilityto,
say, inhibit the enzyme aromatase in vitro.
RodentToxicities ofConcern and
Reference Chemicals
A precondition for framing toxicological
definitions is the existence of a list ofsen-
tinel rodent toxicities related to each type
of endocrine disruption, together with a
database of reference positive control
chemicals for the toxicities named, as
developed in other branches of toxicology
(25,26). Despite their clear importance,
neither ofthese lists has yet been finalized
by the scientific community. In the case of
estrogenicity, estradiol or DES are available
as positive control agents, but even in these
cases the estrogen-specific toxicities expect-
ed are not universally agreed upon.
In the absence of agreement about a
range of reference endocrine disruptors, it
will be difficult to assess the general sensi-
tivity ofexisting or emerging tests. Equally,
the current absence ofagreement on chem-
icals that are inactive as endocrine disrup-
tors makes it impossible to evaluate the
specificity ofemerging in vitro assays, or to
discern the lower level of activity in any
predictive assay that would be expected to
lead to significant endocrine toxicities in
vivo. This absence of in vivo toxicity data
for a range oftoxic and nontoxic reference
chemicals must be remedied in order to
have a sound research foundation upon
which to build an effective regulatory strat-
egy. Individual research groups or regulato-
ry authorities may know of such reference
chemicals, but unless these can be shared
with the general scientific community, they
effectively do not exist.
Structure-activityRelationships
The derivation ofstructure-activity relation-
ships (SARs) in this areawould aid theprior-
itization ofchemicals for testing. However,
McLachlan (2) and Katzenellenbogan (27)
have pointed out the current difficulty of
reconciling chemical structure with the wide
range of chemical substances reported to
have one or other of the several different
endocrine-disrupting properties. It is antici-
pated that useful SARs will exist in situations
where specific effects are studied within dis-
crete chemical series, using standardized
bioassays and clear criteria for activity.
Waller et al. recently described one such
approach (28). Nonetheless, it is important
to acknowledge that SARs derived from in
vitro studies may differ significantly from
SARs derived from studies conducted in
vivo. Furthermore, it is unlikely that any
general SARs capable of encompassing all
categories of endocrine disruptors will be
developed.
The report that intraperitoneal injec-
tion ofhigh dose levels ofthe solvents eth-
ylene glycol and dimethyl formamide to
rainbow trout resulted in increased levels of
vitellogenin mRNA (29) was unexpected,
given that these chemicals are structurally
remote, on all counts, from the endoge-
nous estrogen receptor agonist estradiol.
The data in question could indicate one of
three possible things, each ofwhich is per-
tinent to the construction ofSAR databases
for endocrine disruption. First, if they are
taken as evidence of the estrogenicity of
these two chemicals, they illustrate the cur-
rent absence of understanding of the criti-
cal chemical features required for
endocrine-disrupting activity. A second
possible explanation is that these chemicals
activated the estrogen receptor by inducing
a change in its conformation, as opposed to
binding to the receptor. Ifthis explanation
were confirmed, it would open up a new
area of chemical estrogenicity whose toxi-
cological significance is presently unclear,
and which would require the derivation of
a separate SAR database. A third possible
explanation is that changes to vitellogenin
mRNA levels, observed without confirm-
ing commensurate changes in protein lev-
els, may not provide a reliable indicator of
the estrogenic activity of chemicals.
Determination of which of these three
explanations is correct will require further
studies, and, prior to the conclusion of
those studies, it would be inappropriate to
enter either of these two solvents into any
SAR database. This discussion therefore
reverts to the critical need for agreed-upon
definitions of endocrine activities as a pre-
cursor to the derivation ofSARs and assays
for those activities.
In VitroAssays
The crucial problem is that there are no
standard criteria for the selection, develop-
ment, or grouping ofassays into test batter-
ies or tiers, or for assessing their sensitivity,
specificity, and relationship to each other.
Such questions need immediate attention,
because chemicals are already showing dif-
ferent qualitative responses between similar
in vitro assays, between in vitro and in vivo
assays, and between different routes of
administration in vivo (30). For example,
several yeast assays having the human estro-
gen receptor stably integrated into their
genome are in current use. These assays
have subtly different reporter gene con-
structs and variable numbers of estrogen
response elements, and it is currently
unclear what effect, ifany, these differences
will have on experimental outcomes.
Similarly, many laboratories are using one
or more ofa varietyoftransiently transfect-
ed receptor cell lines, and some of these
may be difficult to transfer into routine
regulatory use (compare the level of stan-
dardization achieved rapidly, and essential-
ly, for the Salmonella mutation assay).
Finally, some of the currently available in
vitro assays, although potentially valuable,
are complex and/or time consuming to
conduct, as illustrated by the fish primary
hepatocyte vitellogenin assay (31). The pre-
sent proliferation of in vitro assays will
inevitably continue apace with revelations
of the complexity of normal sexual repro-
duction (32). Therefore, prior to the for-
mal, regulatory adoption of any of these
assays, it is vital that the differences
between existing assays be elucidated and
critically examined, robust versions of the
preferred and validated assays be developed
for routine use, and an agreed-upon frame-
work in which these assays should be used
be derived. Failure to meet these needs will
lead to delays in effective implementation
similar to those that accompanied the
introduction ofmutagenicity assays.
Among the in vitro assays so far
described, with the obvious exception of
the fish hepatocyte assay and the possible
exception of the receptor-based yeast
assays, none appear to be metabolically
competent. The use of in vitro mutagenici-
ty assays in the absence of liver enzymes,
e.g., S9 mix, would lead to the nondetec-
tion of many mammalian mutagens and
carcinogens, and a similar problem should
be anticipated in this area. For example,
Shelby et al. (33) reported that the in vivo
xenoestrogen methoxychlor is unable to
bind to isolated estrogen receptors or acti-
vate those receptors in a mammalian cell
transactivation assay. This observation led
to the independent study ofthe same sam-
ple of methoxychlor in a yeast human
estrogen receptor transactivation assay,
with the goal of confirming its inactivity
and establishing the importance of auxil-
iary metabolism. In fact, it was found to
give apotent direct-actingpositive response
in the yeast assay, presumably reflecting the
ability ofthe yeast cells to demethylate the
methoxy groups yielding the active estro-
genic phenol derivative (34). This example
confirms that the issue of metabolism in
vitrohas the potential to confound the vali-
dation ofmammalian cell in vitroassays.
In addition to the general problem of
metabolism and, again, based on experi-
ence gained with mutagenicity assay devel-
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opment, it will be helpful if investigators
can rapidly agree which assays are unreli-
able or nonspecific, and then share that
conclusion openly. As an example, the
polyclonal nature ofMCF-7 cells (17) and
the insensitivity of some of the clones to
estradiol (35), coupled with the problem of
the assay's low specificity, suggest that this
assay will have limited value for general
screening purposes, despite the fact that it
can be performed adequately in some labo-
ratories. There is a need for such a clear
conclusion to be openly agreed upon in the
scientific community because, in its
absence, the assay will continue to be used
to define potential endocrine disruptors.
All new test systems should be scrutinized
by the broader scientific community before
they are accepted for general use.
It is proposed that the development of
in vitro assays for potential endocrine dis-
ruptors should be led by the naming ofsig-
nificant toxicities that are consequent to
disruption ofthe endocrine system ofintact
organisms, followed by attempts to model
these effects in vitro. When appropriate,
such assays should then be refined to pro-
duce robust test protocols suitable for gen-
eral use. This is in contrast to the uncoordi-
nated proliferation ofsuperficially validated
assays that act as a brake on progress and
lead to the generation of potentially large
amounts of uninterpretable data. The need
for scientific caution in progressing this new
area oftoxicology is illustrated by the failure
to confirm (35,36) the recent report by
Arnold et al. (37) ofsynergism ofestrogenic
activity observed in vitro between a range of
environmental chemicals.
In VivoAssays
It is general practice in toxicology to screen
for a potential toxic activity in vitro and to
then confirm the expression ofthat activity
in vivo before attributing a given toxic
property to the test agent. For this and sev-
eral other reasons outlined in this article, in
vivo assays will assume a dominant position
in screening strategies and risk assessment
processes for endocrine disruption.
Further, the trend common to other
branches of toxicology of combining a
range ofend points in a single test protocol
probably will apply equally to in vivo assays
for endocrine disruption. However, an
inevitable corollary to the use of multiple-
end point assays is that one is forced to
rank end points, often in the absence of
guiding data, when qualitatively divergent
responses are obtained among the several
end points being monitored. This indicates
the need for an established hierarchy of
endpoint sensitivities for studying
endocrine disruption in a given organism.
In addition, the decision to conduct an
assay in vivo carries with it a range ofdeci-
sions regarding the choice of test species
and strain, route of administration, and
duration ofdosing. The rodent uterotroph-
ic assay illustrates why these generic prob-
lems should be discussed before, rather
than after, the regulatory protocols for in
vivo assays are fixed. The uterotrophic assay
is often referred to as the gold standard of
estrogenic activity in vivo. However, the
data upon which this reputation is based
were derived using a variety of protocols.
The key variables were the use of rats or
mice; the use of immature, hypophysec-
tomized, or ovariectomized animals; the
use of subcutaneous, intraperitoneal injec-
tion or oral administration of the test
agent; and a dosing duration ofbetween 3
and 6 days. Furthermore, some investiga-
tors recommend concomitant assessment of
associated markers of estrogenic activity,
such as vaginal opening, vaginal cornifica-
tion, uterine epithelial cell height, or stro-
mal proliferation (38,39).
To decide which of these many vari-
ables are important to the overall sensitivity
of an assay will require assessment of a
range of appropriate positive and negative
endocrine disruptors. Similarly, it will be
important to study the sensitivity and
specificity of proposed estrogen action
markers before they can replace existing
markers. For example, lactoferrin mRNA
levels in the immature mouse uterus can be
increased several hundredfold when
exposed to an estrogen (40), but before this
can be developed into a replacement for
the uterotrophic assay, it will be necessary
to evaluate the specificity of this response,
and to establish that the estrogen and
growth factor response elements in the
mouse uterus lactoferrin gene are represen-
tative of that in humans. The failure to
broach such basic questions in genetic toxi-
city research has led to the development of
a large number of competing in vivo tech-
niques with no general agreement on
which ofthem are complementary to other
assays andwhich are redundant.
Multiple Mechanisms ofAction
Agreement on a testing strategy to detect
significant mammalian and wildlife estro-
gens would be relatively easy to achieve,
and several such proposals have already
been made (38,39,41). However, such a
strategy would not be expected to predict
endocrine toxicities associated with distur-
bances to normal steroid hormone synthe-
sis or metabolism, thyroid gland function,
or pituitary and hypothalamic feedback
control mechanisms. Such effects will be
difficult, if not impossible, to simulate in
vitro, and this again indicates the need for a
high level of reliance on acute or subacute
whole organism assays. For example,
although some of the in vivo effects of
PCBs may be predicted by in vitro assay
results, particularly those effects mediated
by direct receptor interactions, this will not
always be true. As an example, it is unlikely
that any cell-based assay could anticipate,
at least for the correct reason, the ability of
certain PCBs to increase the weight of rat
testes (42). This is because the effect is
dependent upon PCB-induced hypothy-
roidism preventing the cessation of Sertoli
cell division on about day 16 postpartum,
an effect that is probably independent of
the weak uterotrophic activity seen for
PCBs in the 'rat (43). Likewise, the testicu-
lar effects reported for BBP (13) are unlike-
ly to be associated mechanistically with its
mitogenicity to MCF-7 cells, just as the
endocrine toxicities ofp,p'-DDE are most
probably mediated by its antiandrogenic
properties, rather than by its initially
defined estrogenic properties (44).
Differentiation ofToxicities and
Effects
The present uncertainty regarding the in
vivo toxicities to expect of a chemical that
has shown activity in vitrocould lead to the
measurement ofa wide range ofparameters
in follow-up in vivo studies. Such toxico-
logical fishing exercises might sometimes
be justified, but to be useful they will
require the separate recognition of signifi-
cant toxicities and transient adaptive
effects. For example, a small chemically
induced change in the levels of sex hor-
mones in a rodent may be devoid of toxic
significance. A different example is provid-
ed by the measurement of the anogenital
(AG) distance in neonatal rats whose
mothers have been exposed to a potential
endocrine-disrupting agent. This end point
is a potentially valuable marker of
endocrine disruption, but it has been little
studied to date, and few control data have
been published. Therefore, it is legitimate
to interpret with caution alterations in this
parameter in cases where the effect resolves
byweaning and the pups show normal sex-
ual development and function. Such effects
may be ofvalue to explain the observation
ofa recognized endocrine toxicity, but they
may be of little value when the effects
themselves constitute the only evidence for
endocrine disruption. This is in contrast to
situations where an irreversible change in
AG distance is subsequently accompanied
by other effects, such as a change in the
time ofvaginal opening or preputial sepa-
ration, or reduced fertility of the adult
rodents. This may change with the acquisi-
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tion of a larger database for AG distance
and other relatively new markers of
endocrine disruption, but in the meantime
it is dangerous to interpret such effects in
isolation. A related example would be a
transient induction of the mRNA in male
trout that was not shown to be accompa-
nied by the synthesis of vitellogenin pro-
tein. Distinguishing toxic responses from
transient effects will be particularly impor-
tant in these early days of the study of
endocrine disruption, because it will
enhance the rapid recognition ofendocrine
toxicities of immediate potential relevance
to humans orwildlife.
An IntegratedApproach
Ifthe current concerns turn out to be justi-
fied, the problem posed will not be con-
fined to a few countries. Therefore, it is
important that the many initiatives being
undertaken by individual governments and
chemical industries to assess this issue be
prioritized and developed with some level
ofinternational coordination.
Steps required for the effective regula-
tion ofendocrine-disrupting chemicals:
* International liaison
-Coordinate studies to verify the sus-
pected chemically mediated endocrine
toxicities in wildlife and humans.
- Share research plans.
* Prioritization ofareas ofstudy
- Specification ofkey endocrine disrup-
tion toxicities and mechanisms and
the compilation of a database of
appropriate endocrine toxins.
- Estrogen/androgen receptor-mediated
toxicities to be addressed first.
* Development ofpriority assays
- Identification oftest species to act as
human surrogates andwildlife sen-
tinels.
-Agreement on the necessity for in vivo
assays in this branch oftoxicology.
- Development ofin vitroand in vivo
assays, with attention given to their
practicality, reproducibility, metabolic
capacity, cost, and mechanistic plausi-
bility.
- Definition ofthe relationship
between in vitro assay data and in vivo
assay data in terms oftheirvalue for
risk assessment.
* Development ofregulations
- International agreement on a prelimi-
nary regulatory strategy, to be devel-
oped and further refined with the
acquisition ofnew data.
The divergent testing strategies and reg-
ulatory requirements that resulted from
individual nations' approaches to carcino-
gen screening should act as a particular
warning. However, the task faced on this
occasion is even more complex, because the
chemical disturbance of essentially any
aspect of animal physiology is under con-
sideration. The detailed knowledge
required to respond optimally to this situa-
tion is concentrated in a relatively small
number of endocrinologists around the
world, but they may not be equipped to
advance this broad area of toxicology
unaided. Thus, there is the need for toxi-
cologists, regulators, and endocrinologists
to pool their differing expertise at the inter-
national level.
Key among the priorities suggested
above are the need to continue to support
studies to better define the reality and nature
ofthe hazards posed, and to further investi-
gate the original question of exposure of
wildlife and humans to estrogen and andro-
gen receptor agonists/antagonists. When
progress has been made in these areas, atten-
tion can be given to the development of
assays for other mechanisms of endocrine
disruption. This will involve the develop-
ment ofassays that measure enzyme or hor-
mone levels and activities in vivo. Such tech-
niques may be difficult to refine into robust
regulatory tests. This sequential approach to
the many issues posed will enable coordinat-
ed progress to be made in defined areas. As
general confidence in a core set of assays
grows, consideration should be given to
integrating endpoints into a reduced num-
ber ofassays.
Finally, one should always keep in
mind that the regulation of synthetic
chemicals for endocrine disrupting proper-
ties may not alleviate the observed increases
in human breast and testicular cancer or
the apparent decrease in human sperm
counts and sperm quality reported for
some countries. Therefore, while attending
to one possible contributor to these prob-
lems-synthetic chemicals-we should
remain alert to the possible importance of
alternative contributory factors, such as
diet and lifestyle.
REFERENCES
1. Colborn T, Clement C, eds. Chemically-
induced alterations in sexual and functional
development. Princeton, NJ:Princeton Scientific
Publishing, 1992.
2. McLachlan JA. Functional toxicology: a new
approach to detectbiologically active xenobiotics.
Environ Health Perspect 101:386-387 (1993).
3. Colborn T, vom Saal FS, Soto AM. Develop-
mental effect ofendocrine disrupting chemicals
in wildlife and humans. Environ Health
Perspect 101:378-385 (1993).
4. McLachlan JA, Korach KS, eds. Symposium on
estrogens in the environment. III: Global health
implications. Environ Health Perspect
103(suppl 7):3-178 (1995).
5. National Academy of Sciences. Responsible sci-
ence: ensuring the integrity of the research
process, vol 1. Washington, DC:National
Academy Press, 1992.
6. ECETOC. Environmental oestrogens: a com-
pendium of test methods. ECETOC Doc 33.
Brussels:European Centre for Ecotoxicology and
ToxicologyofChemicals, 1996.
7. Bliley R Food Quality Protection Act of 1996.
104th Congress, 2nd session. Report 104-669,
part 2. Washington, DC:Government Printing
Office, 1996;1-89.
8. Kavlock RJ, Daston GP, DeRosa C, Fenner-
Crisp P, Gray LE, Kaattari S, Lucier G, Luster
M, Mac MJ, Maczka C, et al. Research needs
for the risk assessment of health and environ-
mental effects ofendocrine disruptors: a report
of the U.S. EPA-sponsored workshop. Environ
Health Perspect 104(suppl 4):715-740 (1996).
9. Hill AB. The environment and disease: associa-
tion or causation? Proc R Soc Med 58:295-300
(1965).
10. Ames BN, Gold LS. Too many rodent carcino-
gens. Science 249:970-971 (1990).
11. Purdom CE, Hardiman PA, Bye VJ, Eno NC,
Tyler CR, Sumpter JP. Estrogenic effects of
effluents from sewage treatment works. Chem
Ecol 18:275-285 (1994).
12. Harries JE, Sheahan DA, Jobling S, Matthiessen
P, Neall P, Routledge EJ, Rycroft R, SumpterJ,
Tylor T. A survey of estrogenic activity in
inland waters. Environ Toxicol Chem
15:1993-2002 (1996).
13. Abel M, Giger W, Schaffner C. Behavior of
alkylphenol polyethoxylate surfactants in the
aquatic environment. II. Occurrence and trans-
formation in rivers. Water Res 28:1143-1152
(1994).
14. White R, Jobling S, Hoare SA, Sumpter JP,
Parker MG. Environmental persistent alkylphe-
nolic compounds are estrogenic. Endocrinology
135:175-182 (1994).
15. Jobling S, Sheahan D, Osborne JA, Matthiesen
P, Sumpter JP. Inhibition of testicular growth
in rainbow trout (Oncorhynchus mykiss) exposed
to estrogenic alkylphenolic chemicals. Environ
Toxicol Chem 15:194-202 (1995).
16. Brighty G. The identification and assessment of
oestrogenic substances in sewage treatment works
effluents. R & D technical summary P38. Bristol,
U.K:U.K EnvironmentalAgency, 1996;1-4.
17. Soto AM, Sonnenschein C, Chung KL,
Fernandez MF, Olea N, Serano F. The E-
SCREEN assay as a tool to identify estrogens:
an update on estrogenic environmental pollu-
tants. Environ Health Perspect 103(suppl
7):113-122 (1995).
18. Zakarewski T. A review of in vitro bioassays for
assessing estrogenic substances. Environ Sci
Technol (in press).
19. Sharpe RM, Fisher JS, Millar MM, Jobling S,
Sumpter JP. Gestational and lactational expo-
sure of rats to xenoestrogens results in reduced
testicular size and sperm production. Environ
Health Perspect 103:1136-1143 (1995).
20. Meek MD, Clemons J, Wu ZF, Zackerewski
TB, Martins MA. Assessment of the alleged
estrogen receptor-mediated activity ofphthalate
esters [Abstract 443]. Presented at the 17th
Annual SETAC Meeting, 24-25 November
1996, Washington, DC.
21. Colerangle JB, Roy D. Exposure of environ-
mental estrogenic compound nonylphenol to
noble rats alters cell-cycle kinetics in the mam-
mary gland. Endocrine 4:115-122 (1996).
168 Volume 105, Number2, February 1997 * EnvironmentalHealth PerspectivesCommentary * Challenge ofendocrine-disrupting chemicals
22. Lee PC, Lee W. In vivo estrogenic action of
nonyl phenol in immature female rats. Bull
Environ Contami Toxicol 57:341-348 (1996).
23. Evans GL, Bryant HU, Magee DE, Turner RT.
Raloxifene inhibits bone turnover and prevents
further cancellous bone loss in adult ovariec-
tomized rats with established osteopenia.
Endocrinology 137:4139-4144 (1996).
24. Yang NN, Venugopalan M, Hardikar S,
Glasebrook A. Identification of an estrogen
response element activated by metabolites of
17p-estradiol and raloxifene. Science 273:
1222-1225 (1996).
25. Purchase IFH. An international reference chem-
ical data bank would accelerate the develop-
ment, validation and regulatory acceptance of
alternative toxicology tests. ATLA 18:345-348
(1990).
26. ECETOC. Skin irritation and corrosion: refer-
ence chemicals data bank. ECETOC Technical
Rep No 66. Brussels:European Centre for
Ecotoxicology and Toxicology of Chemicals,
1995.
27. Katzenellenbogen JA. The structural pervasive-
ness of estrogenic activity. Environ Health
Perspect 103(suppl 7):99-101 (1995).
28. WailerCL, OpreaTI, Chae K, ParkH-K, Korach
KS, Laws SC, Wiese TE, Kelce WR, Gray LEJr.
Ligand-based identification of environmental
estrogens. Chem Res Toxicol 9:1240-1248
(1996).
29. Ren L, Medahl A, LechJJ. Dimethyl formamide
(DMFA) and ethylene glycol (EG) are estrogenic
in rainbow trout. Chem Biol Interact 102:63-67
(1996)
30. Mellanen P, Petanen T, Lehtimaki J, Makela S,
Bylund G, Holmbom B, Mannila E, Oikari A,
Santti R. Wood-derived estrogens: studies in
vitro with breast cancer cell lines and in vivo in
trout. Toxicol Appl Pharmacol 136:381-388
(1996).
31. Jobling S, Sumpter JP. Detergent components
in sewage effluent are weakly oestrogenic to fish:
an in vitro study using rainbow trout
(Oncorhynchus mykiss) hepatocytes. Aquat
Toxicol 27:361-372 (1993).
32. Kuiper GGJM, Enmark E, Pelto-Huikko M,
Nilsson S, Gustafsson J.A. Cloning of a novel
estrogen receptor expressed in rat prostate and
ovary. Proc Natd Acad Sci USA 93:5925-5930
(1996).
33. Shelby MD, Newbold RR, Tully DB, Chae K,
Davis VL. Assessing environmental chemicals for
estrogenicity using a combination of in vitro and
in vivo assays. Environ Health Perspect
104:1296-1300 (1996).
34. Ashby J, Lefevre PA, Odum J, Harris CA,
Routledge EJ, Sumpter JP. Synergism between
synthetic oestrogens? Nature 385:494 (1997).
35. Villalobos M, Olea N, BrotonsJA, Olea-Serrano
MF, Ruiz de AlmodovarJM, Pedraza V. The E-
SCREEN assay: a comparison of different
MCF7 cell stocks. Environ Health Perspect 103:
844-850 (1995).
36. Ramamoorthy K, Wang F, Chen I-C, Norris
JD, McDonnell DP, Leonard LS, Gaido KW,
Bocchinfuso WP, Korach KS, Safe S. Estrogenic
activity of a dieldrin/toxaphene mixture in the
mouse uterus, MCF-7 human breast cancer cells
and yeast-based estrogen receptor assays: no
apparent synergism. Endocrinology (in press).
37. Arnold SF, Klotz DM, Collins BM, Vonier PM,
Guillette Jr. LJ, McLachlan JA. Synergistic acti-
vation of estrogen receptor with combinations
of environmental chemicals. Science
272:1489-1492 (1996).
38. Reel JR, Lamb JC, Neal BH. Survey and assess-
ment of mammalian estrogen biological assays
for hazard characterization. Fundam Appl
Toxicol 34:288-305 (1996).
39. O'Connor JC, Cook JC, Craven SC, Van Pelt
CS, Obourn JD. An in vivo battery for identify-
ing endocrine modulators that are estrogenic or
dopamine regulators. Fundam Appl Toxicol
33:182-195 (1996).
40. Teng C. Mouse lactoferrin gene: a marker for
estrogen and epidermal growth factor. Environ
Health Perspect 103(suppl 7):17-20 (1995).
41. Ashby J. Endocrine modulation of human
reproduction by environmental chemicals.
Environ Toxicol Pharmacol (in press).
42. Cooke PS, Zhao Y, Hansen LG. Neonatal poly-
chlorinated biphenyl treatment increases adult
testis size and sperm production in the rat.
ToxicolAppI Pharmacol 136:112-117 (1996).
43. Li M-H, Hansen LG. Responses ofprepubertal
female rats to environmental PCBs with high
and low dioxin equivalencies. Fundam Appl
Toxicol 33:282-293 (1996).
44. Kelce WR, Wong C, Gray LE Jr, Wilson EM.
Environmental antiandrogens. Fundam Appl
Toxicol 2: 9-11 (1996).
iEnvironmental
Society
The 28th Annual Environmental Mutagen Society Meeting willbe held atthe Hyatt Regency Hotel in
Minneapolis, Minnesota, April 19-24,1997. The Environmental Mutagen Society is an international soci-
ety whose purpose is to engage in scientific investigation and disseminationofinformation relating to the
field ofmutagenesis and to encourage the study ofmutagens in the human environment in particular,
how mutagens may affect public health. The annualmeeting brings together scientists from academia,
industry, and government to discuss recentfindings in the fields ofmutagenesis and molecular genetics
and their application to regulation and safety evaluation.
For more information, please contact Sid Aaron, Pharmacia and Upjohn Inc., 301 Henrietta St.,
Kalamazoo, MI 49007; (616) 833-1399, Fax (616) 833-9722, email: saaron~am.pnu.com or the EMS
business office, 11250-8 Roger Bacon Dr., Suite 8, Reston, VA 22090; (703) 437-4377, Fax (703) 435-4390,
email: emsdmg~aol.com
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